# Should our health plan cover GLP-1s?

Source: https://www.getprescience.com/guides/should-our-health-plan-cover-glp1s
Author: Aditya Jain, MD, Cofounder and COO, Prescience
Published: 2026-11-08
Updated: 2026-11-08
Cite as: Aditya Jain, MD. "Should our health plan cover GLP-1s?." Prescience, November 8, 2026. https://www.getprescience.com/guides/should-our-health-plan-cover-glp1s

GLP-1 coverage can be a useful chronic disease benefit, but employers should evaluate the covered diagnoses, clinical support, employee cost and sustainable budget together. Coverage for diabetes does not automatically include obesity treatment. Here is how I would compare the options before promising coverage to a team.

- **Coverage varies by:** Drug, indication and policy
- **Employer budget:** Use multiple utilization scenarios
- **FDA approval:** Does not guarantee coverage
- **Clinical decisions:** Stay with the patient and clinician

## Start with the condition being treated

I would consider GLP-1 coverage as part of a serious chronic disease benefit, then test whether the plan can deliver it consistently. The first question is not whether a drug is popular. It is which diagnosis the policy covers, which medicines are on its formulary, and what happens after the first prescription. A promise to cover weight treatment means little if members cannot find a prescriber or afford the pharmacy bill.

Semaglutide and tirzepatide are ingredients, not interchangeable coverage categories. Different branded products have different approved uses. A diabetes prescription and an obesity prescription can therefore receive different decisions even when the products are related. Ask for the actual formulary and written clinical criteria. Do not infer weight-management coverage from an insurer saying that it covers GLP-1 medicines for diabetes.

There are also approved uses beyond the simple diabetes-versus-weight-loss distinction. In March 2024, FDA approved Wegovy to reduce serious cardiovascular events in adults with established cardiovascular disease and obesity or overweight. In December 2024, FDA approved Zepbound for moderate to severe obstructive sleep apnea in adults with obesity. These approvals describe particular patient populations. They do not mean every person seeking weight loss has the same expected benefit, or that every employer plan must cover the medicine. Both indications use the medicines with reduced-calorie diet and increased physical activity; these are examples of approved uses, not a complete current label summary.

## Separate clinical benefit from a savings promise

As a physician, I do not treat obesity as a failure of willpower. It is a chronic condition, and effective treatment can require medication alongside nutrition, physical activity and ongoing clinical support. NIDDK explains that weight-management medicines are prescribed using factors such as body mass index and weight-related health problems. A clinician must also consider other medicines, medical history, adverse effects and the patient's goals. An employer should fund an appropriate process rather than try to make those judgments itself.

Clinical benefit is not the same as a guarantee that the employer will spend less next year. Avoided complications may occur over a longer period, and some employees will change jobs or insurance before then. I would not use a fixed assumed churn percentage to decide the benefit. Nor would I describe every person who stops treatment as wasted spending: stopping may reflect side effects, a clinical decision, cost or lack of access. Ask why treatment stopped before deciding that the program failed.

If a vendor promises that prescriptions will pay for themselves, ask for the comparison group, time horizon and expenses included. Are results measured for everyone who started, or only those who stayed in the program? Does the savings model count employer-paid fees and medication after rebates? Treat a forecast of fewer hospital visits as a hypothesis to evaluate, not as cash available to fund this year's premium.

## What a useful coverage policy should answer

**Questions to resolve before enrollment**

| Issue | What to request |
| --- | --- |
| Covered use | The diagnoses and products covered, including any exclusions. |
| Authorization | Written starting criteria, renewal criteria and an appeal route. |
| Member cost | The applicable deductible, copay or coinsurance and dispensing rules. |
| Clinical support | Who monitors treatment, manages side effects and coordinates with the regular clinician. |
| Continuity | What happens after a job change, formulary change or authorization expiry. |

A prior authorization can check whether a prescription meets the plan's criteria, but it also creates work for patients and clinicians. Ask who completes the paperwork and who follows up when records are missing. A benefit that requires an employee to spend weeks relaying messages between the pharmacy and prescriber is not the same service as a benefit with a named team managing that process.

Renewal criteria matter as much as starting criteria. Ask what the plan requires when a member reaches a healthier weight while taking treatment. Do not assume that reaching a target automatically means medication is no longer needed. Treatment duration belongs in a conversation between the patient and clinician, within the plan's documented rules. Ask the administrator how it handles a temporary interruption, intolerance or a switch to another covered medicine.

## Budget with utilization scenarios, not a list price

For a small employer buying an insured plan, the immediate budget question is the quoted premium and benefits available. You may not have the option to turn coverage on independently. Ask for comparable quotes with the requested benefit clearly identified. If an administrator instead presents a claims budget, separate the pharmacy estimate from clinical program fees and administration. Manufacturer list price, a temporary cash offer and the plan's net cost are three different numbers.

**A sensitivity test for a 40-person company**

Illustrative planning assumptions, not a drug price quote or expected utilization. Assume 40 enrolled employees, 4 users treated for 12 months, and $600 monthly net medication cost per user. Dependents and program fees are excluded. The assumed net cost is solely a sensitivity input, not a manufacturer list price, discount program or Prescience benefit promise.

- Annual medication cost per user: $600 × 12: $7,200
- Four users: $7,200 × 4: $28,800
- Equivalent monthly cost per enrolled employee: $28,800 ÷ 40 ÷ 12: $60
- Eight users at the same assumed cost: $57,600 annually, or $120 per employee monthly

Doubling use doubles this simplified budget. It does not predict the premium increase on an insured policy. Replace both utilization and net price with documented assumptions from the actual proposal.

Run the same exercise with fewer months of treatment, more eligible dependents and a higher net price. Show the range to the person who owns the benefits budget. Avoid silently counting medical savings to make the number fit. If the benefit depends on a rebate, ask when it is received, which prescriptions qualify and who retains it. A lower headline price can be offset by a higher program fee or narrower access.

## Test the employee journey before buying

1. **Confirm the exact policy** Ask the carrier or administrator to identify the covered drug, indication and plan year in writing. A sales presentation is not enough to resolve an exclusion.
2. **Trace a new prescription** Have the administrator explain who receives the prescription, obtains authorization, tells the member their cost and resolves a pharmacy rejection. Use a fictional case.
3. **Trace an existing patient** Ask how prior treatment is documented and whether a new authorization is needed at the coverage transition. Confirm the process before communicating continuity to employees.
4. **Assign an escalation contact** Name the benefits contact for administrative problems and the clinical contact for treatment questions. HR should not become the place employees disclose diagnoses.
5. **Review after launch** Use aggregate access measures such as unresolved authorizations and time to a decision. Do not ask a manager to track individual employees' weight or prescriptions.

An employee survey can ask whether prescription affordability and access to chronic care are priorities without collecting a list of diagnoses. If the group is very small, even aggregate reporting can reveal someone's treatment. Ask the administrator to suppress small counts and avoid medical details in employer reports. The decision to offer a benefit should be based on a policy for the eligible group, not on assumptions about particular coworkers' bodies.

## Cash offers and compounded products need a separate review

Employees may see cash programs that appear cheaper than the insured pharmacy price. Before presenting one as an alternative, confirm eligibility, the exact product and dose, refill price, expiration terms and whether spending counts toward the plan's deductible or out-of-pocket limit. A temporary discount is not a durable employer benefit. Employees should also understand which clinician follows them if they leave the program.

Compounded versions are not FDA-approved generics. FDA says unapproved versions do not undergo its premarket review for safety, effectiveness and quality, and has reported concerns including dosing errors and misleading marketing. Do not build a benefits proposal on an assumption that a compounded product is equivalent to an approved one. Questions about an individual patient's clinical need belong with their licensed clinician and pharmacy.

The employer's job is to understand the offered benefit and communicate it accurately. It should not tell employees where to source a medicine outside their care relationship. If a vendor bundles a prescription with coaching, ask whether coaching continues if medication is stopped and whether the member can work with their existing clinician. Access should remain understandable when the patient's circumstances change.

## When I would choose each approach

I would favor a sustainable covered benefit when the budget can support it, the authorization rules are clear and members can obtain ongoing care. If the available quote is unaffordable, I would ask for other plans and contributions before promising a benefit the company may withdraw at the next renewal. A narrower policy should be described honestly: coverage for diabetes alone is not comprehensive obesity treatment.

For an existing benefit, changes need a transition plan. Ask about members with active authorizations, required communications and appeals before changing carriers or coverage. Keep a record of the options considered and the reason for the decision. Review the benefit with the rest of the plan, including primary care, behavioral health, nutrition support and employee cost sharing. A drug benefit cannot substitute for an accessible care system.

At Prescience, our physician-led care navigation helps members understand coverage and find appropriate care. That does not mean every prescription or indication is covered. Ask us for the proposed plan's actual drug benefit and rules before choosing it. I want an employer to understand what an employee can use, what they will pay and who helps when something goes wrong.

> **Prescience Diamond: A company health plan with an effective $0 deductible.** Ask us how GLP-1s are covered in your quote. Our physician-led care team helps members understand coverage, authorizations and the care around a prescription.
> - **An effective $0 deductible** and simple copays shown before a visit
> - **A broad national PPO network,** plus providers we contract with directly
> - **24/7 physician-led care navigation** that books visits and explains costs
> - **Usually 10–20% below comparable fully insured coverage,** fixed in your quote, with no admin fees
> Best for teams of about 15 or more that want one great group plan. [Get a Diamond quote](https://www.getprescience.com/get-started?p=Employer&product=diamond)

**Compare the written coverage policy before choosing a plan**

For an employer plan, review covered services, employee cost-sharing and support alongside the budget. Start the proposal with the employee census; individual treatment decisions remain between the member and their clinician.

[Compare coverage for my team](https://www.getprescience.com/quote)

## Frequently asked questions

**Does covering GLP-1s for diabetes include weight loss?**

Not necessarily. Coverage depends on the product, indication, formulary and policy exclusions. Ask for the written obesity-treatment benefit.

**Does FDA approval require my plan to cover a drug?**

FDA approval and insurance coverage are separate decisions. Review the exact policy and applicable coverage requirements.

**Are Wegovy and Zepbound used only for weight loss?**

No. Wegovy has an approved cardiovascular risk-reduction indication for certain adults. Zepbound has an approved indication for moderate to severe obstructive sleep apnea in adults with obesity.

**Will the benefit save money in the first year?**

Do not assume that. Clinical benefits, claims savings and employer premiums are different measures with different time horizons.

**Should employees stop once they reach a target weight?**

That is a clinical question. The employee should discuss ongoing treatment with their clinician and check the plan's renewal criteria.

**Can a small employer add coverage to any plan?**

Not necessarily. Available benefits depend on the insurer and product. Request written quotes that identify the coverage being offered.

**Are compounded versions the same as approved drugs?**

No. Compounded drugs are not FDA-approved, and FDA has identified safety and quality concerns with unapproved GLP-1 products.

**Should HR ask who is taking these medicines?**

HR should focus on access and benefits administration. Use privacy-protective feedback and aggregate reporting rather than collecting individual treatment details.

## Sources

- [FDA, Wegovy cardiovascular indication](https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-reduce-risk-serious-heart-problems-specifically-adults-obesity-or)
- [FDA, Zepbound sleep apnea indication](https://www.fda.gov/news-events/press-announcements/fda-approves-first-medication-obstructive-sleep-apnea)
- [NIDDK, Prescription medications for overweight and obesity](https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity)
- [FDA, Concerns with unapproved GLP-1 drugs](https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss)